论文部分内容阅读
应用乳酸脱氢酶释放法对重组白介素2,粗制天然白介素2,重组肿瘤坏死因子和天然免疫活性肽等淋巴因子诱导人PBMNC为LAK细胞以及LAK细胞对靶细胞(人外周血淋巴细胞,人食管癌109细胞株和人红白血病细胞株_(562)的细胞毒作用分别于培养的第4d和第7d进行了检测。结果显示:①四个配伍组和一个重组白介素2组的多克隆LAK细胞攻击溶解109细胞株和K_(562)细胞株的水平波动子28%和66%之间,中位数为47%,而对正常人外周血淋巴细胞均无细胞毒作用;②重组白介素2和粗制天然白介素2配伍培养LAK细胞的增殖协力约高于重组白介素2和重组肿瘤坏死因子组,以及重组白介素2和免疫活性肽组增殖协力的3倍,③在诱导LAK细胞的过程中其增殖量和其细胞毒活性可以不同步。建议临床上治疗晚期肿瘤病人除用LAK细胞和重组白介素2外,首先选用天然白介素2。
Lactogen dehydrogenase release method of recombinant interleukin 2, crude natural interleukin 2, recombinant tumor necrosis factor and natural immune peptides and other lymphokines induce human PBMNC to LAK cells and LAK cells to target cells (human peripheral blood lymphocytes, human The cytotoxicity of esophageal 109 cell line and human erythroleukemia cell line (562) were detected on day 4 and day 7 respectively.The results showed that: (1) The polyclonal LAK of four compatibility groups and one recombinant interleukin 2 Cytotoxicity was observed in 28% and 66% of the 109 cells and K562 cell lines, respectively, with a median of 47%, but no cytotoxic effect on normal human peripheral blood lymphocytes. The proliferation of LAK cells co-cultured with crude natural interleukin 2 was about 3 times higher than that of recombinant interleukin 2 and recombinant tumor necrosis factor, and 3 times of that of recombinant interleukin 2 and immunocompetent peptides. ③ In the process of inducing LAK cells The amount of proliferation and its cytotoxic activity may not be synchronized Treatment of patients with advanced cancer bed except with LAK cells and recombinant interleukin-2, interleukin-natural first choice 2.